Evotec AG – Product Pipeline Review

Global Markets Direct’s, ‘Evotec AG – Product Pipeline Review – 2016’, provides an overview of the Evotec AG’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Evotec AG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Evotec AG

The report provides overview of Evotec AG including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Evotec AG’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Evotec AG’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Evotec AG’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Evotec AG

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Evotec AG’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Evotec AG Snapshot 7

Evotec AG Overview 7

Key Information 7

Key Facts 7

Evotec AG - Research and Development Overview 8

Key Therapeutic Areas 8

Evotec AG - Pipeline Review 11

Pipeline Products by Stage of Development 11

Pipeline Products - Monotherapy 12

Pipeline Products - Partnered Products 13

Partnered Products/Combination Treatment Modalities 14

Pipeline Products - Out-Licensed Products 15

Out-Licensed Products/Combination Treatment Modalities 16

Evotec AG - Pipeline Products Glance 17

Evotec AG - Clinical Stage Pipeline Products 17

Phase II Products/Combination Treatment Modalities 17

Phase I Products/Combination Treatment Modalities 18

Evotec AG - Early Stage Pipeline Products 19

Preclinical Products/Combination Treatment Modalities 19

Discovery Products/Combination Treatment Modalities 20

Evotec AG - Drug Profiles 21

EVT-201 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

EVT-401 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Drug to Inhibit KDM for Oncology 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Drugs for Endometriosis 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

EVT-070 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

EVT-601 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

EVT-701 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

EVT-801 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Small Molecules for Pain 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Small Molecules to Inhibit PDE10A for Schizophrenia and Psychosis 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Cell Therapy for Type 1 Diabetes and Type 2 Diabetes 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Drug for Kidney Diseases 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Drugs for Alzheimer's Disease 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Drugs for Multiple Sclerosis 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Drugs for Tissue Fibrosis 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Drugs to Inhibit FGFR3 for Bladder Cancer 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Drugs to Target EEM for Type 1 Diabetes and Type 2 Diabetes 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Induced Pluripotent Stem Cells for Amyotrophic Lateral Sclerosis 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Small Molecules for Chronic Kidney Disease 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Small Molecules for Dysferlinopathies 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Small Molecules for Glioblastoma Multiforme 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Small Molecules for Huntington Disease 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

Small Molecules for Inflammation 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

Small Molecules for Multiple Sclerosis 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

Small Molecules for Neurodegenerative diseases 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

Small Molecules for Solid Tumor 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Small Molecules to Agonize Orexin Receptor 2 for Nacrcolepsy 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

Small Molecules to Inhibit PGB for Bacterial Infections 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Evotec AG - Pipeline Analysis 50

Evotec AG - Pipeline Products by Target 50

Evotec AG - Pipeline Products by Route of Administration 51

Evotec AG - Pipeline Products by Molecule Type 52

Evotec AG - Pipeline Products by Mechanism of Action 53

Evotec AG - Recent Pipeline Updates 54

Evotec AG - Dormant Projects 55

Evotec AG - Discontinued Pipeline Products 56

Discontinued Pipeline Product Profiles 56

EVT-301 56

sembragiline 56

ocaperidone 56

REN-1654 56

REN-213 56

REN-850 56

Evotec AG - Locations And Subsidiaries 57

Head Office 57

Other Locations & Subsidiaries 57

Appendix 59

Methodology 59

Coverage 59

Secondary Research 59

Primary Research 59

Expert Panel Validation 59

Contact Us 59

Disclaimer 60

List of Tables

List of Tables

Evotec AG, Key Information 7

Evotec AG, Key Facts 7

Evotec AG – Pipeline by Indication, 2016 9

Evotec AG – Pipeline by Stage of Development, 2016 11

Evotec AG – Monotherapy Products in Pipeline, 2016 12

Evotec AG – Partnered Products in Pipeline, 2016 13

Evotec AG – Partnered Products/ Combination Treatment Modalities, 2016 14

Evotec AG – Out-Licensed Products in Pipeline, 2016 15

Evotec AG – Out-Licensed Products/ Combination Treatment Modalities, 2016 16

Evotec AG – Phase II, 2016 17

Evotec AG – Phase I, 2016 18

Evotec AG – Preclinical, 2016 19

Evotec AG – Discovery, 2016 20

Evotec AG – Pipeline by Target, 2016 50

Evotec AG – Pipeline by Route of Administration, 2016 51

Evotec AG – Pipeline by Molecule Type, 2016 52

Evotec AG – Pipeline Products by Mechanism of Action, 2016 53

Evotec AG – Recent Pipeline Updates, 2016 54

Evotec AG – Dormant Developmental Projects,2016 55

Evotec AG – Discontinued Pipeline Products, 2016 56

Evotec AG, Subsidiaries 57

List of Figures

List of Figures

Evotec AG – Pipeline by Top 10 Indication, 2016 9

Evotec AG – Pipeline by Stage of Development, 2016 11

Evotec AG – Monotherapy Products in Pipeline, 2016 12

Evotec AG – Partnered Products in Pipeline, 2016 13

Evotec AG – Out-Licensed Products in Pipeline, 2016 15

Evotec AG – Pipeline by Target, 2016 50

Evotec AG – Pipeline by Molecule Type, 2016 52

Evotec AG – Pipeline Products by Mechanism of Action, 2016 53

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared